The in vitro activity of
luliconazole (NND-502), a novel
imidazole antifungal agent, against dermatophytes and several other groups of medically important fungi including the rare causative agents of
dermatomycoses, was studied. The
luliconazole susceptibility tests were performed with a total of 58 fungal strains of 23 species of fungi grouped into dermatophytes, dematiaceous fungi, hyaline hyphomycetes, yeastlike fungi, and zygomycetes using a broth microdilution method with RPMI 1640 medium. The minimum inhibitory concentration (MIC) values for
luliconazole were compared with those of three reference drugs,
lanoconazole (LCZ),
bifonazole (BFZ), and
terbinafine (TBF), all of which have been popular for the topical treatment of
dermatophytosis,
cutaneous candidiasis, and other superficial
fungal infections in Japan.
Luliconazole inhibited growth of all filamentous fungi except zygomycetes at low concentrations (MIC, < or =0.004-0.125 microg/ml), with dermatophytes being most susceptible (MIC, < or =0.004-0.008 microg/ml). The susceptibility of these filamentous fungi to
luliconazole was almost equal to that to LCZ, and surpassed TBF and BFZ, although to a lesser extent; yeastlike fungi were also susceptible to
luliconazole (MIC, 0.125-4 microg/ml). Again the anti-yeastlike fungi activity of
luliconazole was at the same level as LCZ and was greater than that of BFZ and TBF. In contrast to BFZ and TBF, however,
luliconazole and LCZ were virtually inactive against zygomycetes.